Back to Search
Start Over
Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea
- Source :
- Thyroid. 30:732-738
- Publication Year :
- 2020
- Publisher :
- Mary Ann Liebert Inc, 2020.
-
Abstract
- Background: Lenvatinib, an oral multikinase inhibitor, is the latest addition to the treatment options for radioactive iodine (RAI)-refractory progressive differentiated thyroid carcinoma (DTC). Th...
- Subjects :
- Male
Oncology
medicine.medical_specialty
Endocrinology, Diabetes and Metabolism
Antineoplastic Agents
030209 endocrinology & metabolism
Iodine Radioisotopes
Thyroid carcinoma
Multikinase inhibitor
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Endocrinology
Refractory
hemic and lymphatic diseases
Internal medicine
Republic of Korea
Humans
Medicine
Thyroid Neoplasms
Progression-free survival
Aged
business.industry
Phenylurea Compounds
Treatment options
Middle Aged
Progression-Free Survival
Survival Rate
Treatment Outcome
Multicenter study
chemistry
030220 oncology & carcinogenesis
Retreatment
Quinolines
Female
Radioactive iodine
business
Lenvatinib
Subjects
Details
- ISSN :
- 15579077 and 10507256
- Volume :
- 30
- Database :
- OpenAIRE
- Journal :
- Thyroid
- Accession number :
- edsair.doi.dedup.....4985eb1bd5cc9ad70bb798e44c0de3b8